Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expressi...
Author: cancergrace
Added: 07/01/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2015 Category: Cancer & Oncology Source Type: podcasts
" Toxic Block " -- The Discovery Files
University of Delaware (UD) researchers have discovered a soil microbe that mobilizes an " iron shield " to block the uptake of toxic arsenic in rice. Arsenic occurs naturally in rocks and soils, air and water, plants and animals. It's used in a variety of industrial products and practices, from wood preservatives, pesticides and fertilizers, to copper smelting. Chronic exposure to arsenic has been linked to cancer, heart disease and diabetes. The UD finding gives hope that a natural, low-cost solution--a probiotic for rice plants--may be in sight to protect this global food source from accumulating harmful levels of one o...
Source: The Discovery Files - June 30, 2015 Category: Science Authors: National Science Foundation Source Type: podcasts
Immunotherapy Combinations: Best Balance of Activity and Tolerability?
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which d...
Author: cancergrace
Added: 06/29/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2015 Category: Cancer & Oncology Source Type: podcasts
Helping Patients Manage Melanoma Toxicities
Ways that nurses can help patients with melanoma manage toxicities from treatment.
Richard W. Joseph, MD, oncologist, Mayo Clinic,
Author: onclivetv
Added: 03/23/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 23, 2015 Category: Cancer & Oncology Source Type: podcasts
Preventing and Managing Melanoma Toxicities discussion with Dr. Lacouture
How nurses can help prevent and manage skin toxicities associated with melanoma treatment.
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer
Author: onclivetv
Added: 03/23/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 23, 2015 Category: Cancer & Oncology Source Type: podcasts
Targeting Colon Cancer: Toxicities and Side Effects During Treatment
At the European Society for Medical Oncology (ESMO) 2014 Congress, Johanna Bendell, M.D. (Sarah Cannon Research Institute), discusses patient choice in the selection of a chemotherapy regimen for colo...
Author: vitaloptions
Added: 03/11/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 12, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma
Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma
Author: onclivetv
Added: 02/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 25, 2015 Category: Cancer & Oncology Source Type: podcasts
HER2+ Therapy: Getting Less Toxic All the Time
Drs Kathy Miller and Clifford Hudis discuss at SABCS 2014 recent advances in HER2+ breast cancer, focusing on the growing interest in lowering the toxicity of therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - December 22, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Toxicity as a Biomarker
Dr. Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark discusses Toxicity as a Biomarker at the Kidney Cancer meeting in Chiacgo
Author: kidneycancer
Added: 11/12/2014 (Source: Oncology Tube)
Source: Oncology Tube - November 12, 2014 Category: Cancer & Oncology Source Type: podcasts
Developing CLL Treatment Classes
Recently, many approved and developing CLL therapies have aimed to inhibit rather than destroy cancer cells, often replacing the more toxic chemotherapy standard. BTK and PI3K inhibitor classes have b...
Author: patientpower
Added: 09/25/2014 (Source: Oncology Tube)
Source: Oncology Tube - September 26, 2014 Category: Cancer & Oncology Source Type: podcasts
Bevacizumab's Role in Late-Stage Cervical Cancer
Dr. Maurie Markman discusses the recent FDA approval of bevacizumab for recurrent or late-stage cervical cancer and weighs the benefits of the drug in this setting against its toxicity profile. (Source: Medscape Oncology)
Source: Medscape Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Cure vs. Control in Lymphoma: The Changing Treatment Paradigm
Novel agents emerging for the treatment of lymphoma are offering some patients the opportunity of long-term disease control while avoiding aggressive and highly toxic chemotherapy therapies. For the t...
Author: patientpower
Added: 09/23/2014 (Source: Oncology Tube)
Source: Oncology Tube - September 23, 2014 Category: Cancer & Oncology Source Type: podcasts
Dr George Follows discusses CLL treatment choices and side effects
Different drug combinations have different toxicity profiles, associated complications and efficacy. Requiring lengthy discussion between patients and their doctor and treatment at a centre experience...
Author: PatientPowerEU
Added: 09/16/2014 (Source: Oncology Tube)
Source: Oncology Tube - September 16, 2014 Category: Cancer & Oncology Source Type: podcasts
Managing Toxicities Associated With Regorafenib
Cathy Eng, MD, and Jessica Mitchell, RN, CNP, MPH, discuss the management of side effects associated with regorafenib as a treatment for patients with colorectal cancer.
Get more insight, at http:...
Author: onclivetv
Added: 09/10/2014 (Source: Oncology Tube)
Source: Oncology Tube - September 10, 2014 Category: Cancer & Oncology Source Type: podcasts
